Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Schwabe

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Gastroenterology|June 1, 2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsEdward J Gane, Christian Schwabe, Robert H Hyland, et al.
Expert Opinion on Investigational Drugs|February 2, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)Christopher Wynne, Christian Schwabe, Charlotte Lemech, et al.
Journal of Clinical Pharmacology|August 17, 2018
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune DiseasesChristian Schwabe, Bernd Rosenstock, Thi Doan, et al.
Annals of the New York Academy of Sciences|June 16, 2005
Human decidual relaxin and preterm birthGillian D Bryant-Greenwood, Sandra Y Yamamoto, Kimberly M Lowndes, et al.
Clinical and Translational Science|August 22, 2024
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participantsAnees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, et al.
The Lancet. Gastroenterology & Hepatology|July 8, 2021
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trialMan-Fung Yuen, Xue Zhou, Edward Gane, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesChris J Wynne, Rod B Ellis-Pegler, Devonie S Waaka, et al.
Antiviral Therapy|April 29, 2022
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteersThomas N Kakuda, Jeysen Z Yogaratnam, Christopher Westland, et al.
Antiviral Therapy|June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvirDavid Wyles, Alessandra Mangia, Wendy Cheng, et al.
Antiviral Therapy|April 29, 2022
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adultsEdward Gane, Mina Pastagia, Ullrich Schwertschlag, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Gastroenterology|June 1, 2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsEdward J Gane, Christian Schwabe, Robert H Hyland, et al.
Expert Opinion on Investigational Drugs|February 2, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)Christopher Wynne, Christian Schwabe, Charlotte Lemech, et al.
Journal of Clinical Pharmacology|August 17, 2018
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune DiseasesChristian Schwabe, Bernd Rosenstock, Thi Doan, et al.
Annals of the New York Academy of Sciences|June 16, 2005
Human decidual relaxin and preterm birthGillian D Bryant-Greenwood, Sandra Y Yamamoto, Kimberly M Lowndes, et al.
Clinical and Translational Science|August 22, 2024
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participantsAnees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, et al.
The Lancet. Gastroenterology & Hepatology|July 8, 2021
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trialMan-Fung Yuen, Xue Zhou, Edward Gane, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesChris J Wynne, Rod B Ellis-Pegler, Devonie S Waaka, et al.
Antiviral Therapy|April 29, 2022
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteersThomas N Kakuda, Jeysen Z Yogaratnam, Christopher Westland, et al.
Antiviral Therapy|June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvirDavid Wyles, Alessandra Mangia, Wendy Cheng, et al.
Antiviral Therapy|April 29, 2022
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adultsEdward Gane, Mina Pastagia, Ullrich Schwertschlag, et al.
Pageof 6